Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Gro (Q41104655)

From Wikidata

Jump to navigation Jump to search

scientific article published on 23 November 2015

Language	Label	Description	Also known as
English	Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Gro	scientific article published on 23 November 2015

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Gro (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

9

object named as

Ulrich Germing

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

15

object named as

Carlo Aul

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

Aristoteles A N Giagounidis

6

object named as

Aristoteles Giagounidis

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

Uwe Platzbecker

5

object named as

Uwe Platzbecker

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

11

object named as

Petra Muus

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

2

object named as

Stefan Suciu

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

author name string

Michael Lübbert

1

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

Anne Hagemeijer

3

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

Björn Rüter

4

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

Dominik Selleslag

7

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

Boris Labar

8

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

Helmut R Salih

10

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

Karl-Heinz Pflüger

12

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

Hans-Eckart Schaefer

13

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

Lioudmila Bogatyreva

14

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

Theo de Witte

16

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

Arnold Ganser

17

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

Heiko Becker

18

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

Gerwin Huls

19

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

Lieke van der Helm

20

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

Edo Vellenga

21

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

Frédéric Baron

22

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

Jean-Pierre Marie

23

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

Pierre W Wijermans

24

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

EORTC Leukemia Group and the German MDS Study Group

25

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

23 November 2015

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

Annals of Hematology

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

95

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

191-199

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

Revised international prognostic scoring system for myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2547-0

21 January 2018

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2547-0

21 January 2018

European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2547-0

21 January 2018

Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2547-0

21 January 2018

A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2547-0

21 January 2018

International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2547-0

21 January 2018

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2547-0

21 January 2018

Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation fo

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2547-0

21 January 2018

Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate n

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2547-0

21 January 2018

An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2'-deoxycytidine (decitabine) in 177 patients

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2547-0

21 January 2018

Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2547-0

21 January 2018

Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2547-0

21 January 2018

Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2547-0

21 January 2018

Monosomal karyotype in MDS: explaining the poor prognosis?

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2547-0

21 January 2018

Complex, not monosomal, karyotype is the cytogenetic marker of poorest prognosis in patients with primary myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2547-0

21 January 2018

Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2547-0

21 January 2018

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2547-0

21 January 2018

Monosomal and complex karyotypes as prognostic parameters in patients with International Prognostic Scoring System higher risk myelodysplastic syndrome treated with azacitidine

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2547-0

21 January 2018

Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2547-0

21 January 2018

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2547-0

21 January 2018

Identifiers

10.1007/S00277-015-2547-0

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41104655&oldid=2093509814"